The Psilocybin Patent Race Is On
Earlier this week, NeonMind (NMDBF) filed for four provisional patents. Psilocybin Alpha said, "The provisional patent applications include data derived from NeonMind's initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss.